Oncotarget

Research Papers:

Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes

Melissa M. Norström, Emelie Rådestad _, Berit Sundberg, Jonas Mattsson, Lars Henningsohn, Victor Levitsky and Michael Uhlin

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:23581-23593. https://doi.org/10.18632/oncotarget.8051

Metrics: PDF 1308 views  |   HTML 1344 views  |   ?  


Abstract

Melissa M. Norström1,*, Emelie Rådestad2,*, Berit Sundberg2, Jonas Mattsson2,3, Lars Henningsohn4, Victor Levitsky5,8, Michael Uhlin2,3,6,7

1Pharmaceutical Sciences (PS), Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland

2Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

3Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Huddinge, Sweden

4Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden

5Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Zurich, Switzerland

6Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden

7Department of Applied Physics, Royal Institute of Technology, Stockholm, Sweden

8Current address: Oncology Research, Molecular Partners AG, Zurich, Switzerland

*These authors have contributed equally to this work

Correspondence to:

Emelie Rådestad, e-mail: emelie.radestad@ki.se

Keywords: benign prostatic hyperplasia, prostate-infiltrating lymphocytes, immunophenotyping, cytokine/chemokine profiling, inflammation

Received: December 03, 2015    Accepted: February 28, 2016    Published: March 14, 2016

ABSTRACT

Benign prostatic hyperplasia (BPH) is a common chronic non-malignant condition whose prevalence substantially increases with age. Immune cell infiltration and pro-inflammatory mediators have been implicated in the pathogenesis. Here, we characterized 21 extracellular markers on prostate-infiltrating lymphocytes (PILs) and analyzed expression of 26 soluble proteins in prostate tissue obtained from BPH patients (n = 31). These data were correlated with clinical parameters and compared with peripheral blood mononuclear cells (PBMCs) (n = 10). Increased frequencies of T cells expressing co-inhibitory receptors LAG-3, PD-1, TIM-3 or CTLA-4, and co-stimulatory receptors CD28, OX40 or 4-1BB were observed in BPH tissue compared to PBMCs. These findings are consistent with chronic activation and possible functional exhaustion of PILs that may be further augmented by several identified pro-inflammatory factors, such as IL-8 and MCP-1, promoting inflammation and chemotaxis of immune cells to the prostate. Prostate size and plasma prostate-specific antigen levels positively correlated with IL-8 and MCP-1 concentrations, and frequencies of T cells expressing CTLA-4 and TIM-3. It remains to be established whether the link between inflammation and BPH progression supported by our findings reflects a progressive failure of the immune system leading to decreased immune surveillance and development of prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8051